老虎證券

BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L

Reuters
01/19
BRIEF-Mesoblast Says FDA Acknowledges Effects On Pain Intensity Favor Rexlemestrocel-L

Jan 18 (Reuters) - Mesoblast Ltd MSB.AX:

  • FDA ACKNOWLEDGES EFFECTS ON PAIN INTENSITY FAVOR REXLEMESTROCEL-L, CONFIRMS 12-MONTH REDUCTION IN BACK PAIN SUPPORTS PRODUCT EFFICACY

  • MESOBLAST LTD - SECOND PHASE 3 TRIAL MSB-DR004 OVER 50% ENROLLED

  • MESOBLAST LTD - SIGNIFICANT PAIN REDUCTION AND OPIOID CESSATION IN PHASE 3 TRIAL

  • MESOBLAST LTD - REXLEMESTROCEL-L RECEIVES RMAT DESIGNATION FROM FDA

Source text: ID:nGNX1Qh23k

Further company coverage: MSB.AX

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10